Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.345 EUR | +2.00% | -6.47% | -19.50% |
Apr. 03 | Nanobiotix completes escalation portion of 2020-0123 study | CF |
Apr. 02 | Nanobiotix Completes Dose Escalation Segment of Phase 1 Study Targeting Non-Small Cell Lung Cancer | MT |
Sales 2023 * | 15.31M 16.28M | Sales 2024 * | 19.79M 21.04M | Capitalization | 247M 263M |
---|---|---|---|---|---|
Net income 2023 * | -42M -44.67M | Net income 2024 * | -42M -44.67M | EV / Sales 2023 * | 17.7 x |
Net Debt 2023 * | 24.2M 25.74M | Net Debt 2024 * | 24.35M 25.9M | EV / Sales 2024 * | 13.7 x |
P/E ratio 2023 * |
-6.12
x | P/E ratio 2024 * |
-6.58
x | Employees | 101 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 99.58% |
Latest transcript on Nanobiotix
1 day | +1.53% | ||
1 week | -6.91% | ||
Current month | -6.67% | ||
1 month | -4.14% | ||
3 months | -25.28% | ||
6 months | -14.88% | ||
Current year | -19.88% |
Managers | Title | Age | Since |
---|---|---|---|
Laurent Lévy
CEO | Chief Executive Officer | 53 | 03-03-03 |
Bart van Rhijn
DFI | Director of Finance/CFO | 52 | 21-05-31 |
Chief Tech/Sci/R&D Officer | - | 22-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gary Phillips
CHM | Chairman | 58 | 21-05-24 |
Enno Spillner
BRD | Director/Board Member | 55 | 14-06-17 |
Alain Herrera
BRD | Director/Board Member | 74 | 11-06-22 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-15 | 5.345 | +2.00% | 36,779 |
24-04-12 | 5.24 | -5.24% | 67,348 |
24-04-11 | 5.53 | -1.95% | 33,132 |
24-04-10 | 5.64 | -0.62% | 45,413 |
24-04-09 | 5.675 | -0.70% | 19,099 |
Real-time Euronext Paris, April 15, 2024 at 08:47 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.88% | 263M | |
+1.23% | 42.63B | |
+52.05% | 42.32B | |
+5.72% | 40.26B | |
-9.58% | 27.27B | |
+8.10% | 25.24B | |
-22.42% | 18.78B | |
+2.09% | 12.39B | |
+28.86% | 12.24B | |
+5.78% | 10.95B |
- Stock Market
- Equities
- NANO Stock